Sanara MedTech

SMTI

Market cap $266M

FORT WORTH, TX, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc . (“Sanara,” or the “Company”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skin markets, today announced it will report its third quarter 2025 financial results on Wednesday, November 12, 2025 before the U.S. financial markets open.

SMTI's Surgical segment revenue grew 28% year-over-year in Q1 to $25.8 million. Surgical segment adjusted EBITDA was $4.7 million, while THP correspondingly posted a loss of $2.1 million. Management is looking at strategic alternatives for THP while planning to cap further investments at $6 million.

Seth Yon Appointed President, Chief Executive Officer and Director; Ron Nixon to Remain Executive Chairman FORT WORTH, TX, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skin markets, today announced that Seth Yon, Sanara's President and Chief Commercial Officer, has been appointed to the position of President and Chief Executive Officer and will join the Board of Directors, effective September 15, 2025.

FORT WORTH, TX, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skin markets, today announced that management will present at the Cantor Global Healthcare Conference, which is being held at the New York Marriott Marquis in New York, NY from September 2 – 5, 2025. Management will participate in a fireside chat presentation session on Wednesday, September 3 at approximately 2:45 p.m. Eastern Time.

Sanara MedTech Inc. (NASDAQ:SMTI ) Q2 2025 Earnings Call August 13, 2025 8:00 AM ET Company Participants Elizabeth B. Taylor - Chief Financial Officer Ronald T.

Sanara MedTech Inc. (SMTI) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to a loss of $0.41 per share a year ago.

Net Revenue Increased  28% Year-Over-Year in Q2; Increased 27% Year-Over-Year in First Six Months of 2025 Announces Process to Evaluate Strategic Alternatives for its Tissue Health Plus, LLC Subsidiary FORT WORTH, TX, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skin markets, today reported its financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Summary   ● Net revenue increased 28% to $25.8 million, compared to $20.2 million in the second quarter of 2024.

FORT WORTH, TX, July 15, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc . (“Sanara,” or the “Company”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skin markets, today announced it will report its second quarter 2025 financial results on Wednesday, August 13, 2025 before the U.S. financial markets open.

Pilot program designed to provide real-world evidence in the use of Tissue Health Plus' technology platform FORT WORTH, TX, July 14, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skin markets, today announced the recent launch, through its subsidiary, Tissue Health Plus, LLC (“THP”), of its wound care provider pilot program, a first of its kind, value-based wound care offering designed for payers and risk-bearing entities, as well as value-based primary care companies. “We are pleased to announce that, during the second quarter, THP launched a pilot program in partnership with a wound care provider group delivering at-home care for chronic wounds across six states,” said Sam Muppalla, President and CEO of THP.

Sanara MedTech's surgical revenue grew 26% year-over-year in Q1, with a gross margin of 92%. Surgical adjusted EBITDA was $2.7 million in Q1, while THP correspondingly posted a loss of $2 million. High debt levels and elevated interest expenses are key risks, along with the uncertainty surrounding the commercialization of THP.